pharmaphorum

JUNE 22, 2021

The US-based trial will enrol up to 280 participants aged 18 to 49 and will evaluate the safety of the mRNA vaccine candidate given at several dose levels, as well as its ability to stimulate an immune response against H3N2. billion, including $450 million of milestones from the original 2018 agreement.

Vaccines 114

Vaccines Immunization Immunity 114

Pharmaceutical Technology

OCTOBER 14, 2022

They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018. The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccines 115

Vaccines Research Laboratories Immunization Immunity 115

Express Pharma

AUGUST 31, 2023

CanSino begun researching mRNA technology in 2018 and has built a facility in Shanghai that can produce up to 200 million doses a year, giving it the capacity to provide similar services to other companies, CanSino’s CEO and co-founder Xuefeng Yu told a news agency in an interview.

Vaccines 114

Vaccines Immunization Immunity 114

LifeProNow

APRIL 11, 2023

Under the updated arrangements, Sobi has entered into a direct relationship with Sanofi, replacing the previous participation agreement with AstraZeneca entered into in November 2018. In November 2022, Beyfortus was approved by the European Commission and by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Immunization 130

Immunization Immunity 130

European Pharmaceutical Review

JANUARY 26, 2023

Through the Cancer Drugs Fund (CDF), in 2018, England was the first European country to provide access to a CAR T-cell therapy to treat these blood cancers. CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy 124

Chemotherapy Immunization Immunity 124

European Pharmaceutical Review

SEPTEMBER 29, 2023

Rybrevant and lazertinib Rybrevant is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity. The Phase III clinical trial demonstrated significant improvement in progression-free survival (PFS) in patients receiving Rybrevant with lazertinib compared to osimertinib.

Pharmaceutical Companies 111

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunization 111

pharmaphorum

JANUARY 26, 2021

Under the leadership of CEO Vas Narasimhan, who took over in 2018, the company has focused on using digital technology to engage with both patients and doctors. Sales of spinal muscular atrophy gene therapy Zolgensma have been hit because it requires a course of drugs to suppress the immune system before prescription.

Hospitals 111

Hospitals Immunization Immunity 111

pharmaphorum

JUNE 11, 2021

takeover of Bioverativ in 2018, is designed to block the complement pathway of the immune response, which becomes activated in CAD. In some cases patients can develop life-threatening blood clotting complications. Sutimlimab, which Sanofi acquired via its $11.6

Immunization 96

Immunization Immunity Labelling 96

Pharmaceutical Technology

JANUARY 23, 2023

The management of SLE and LN consists largely of treatment options that are based on highly efficacious steroids or immune-suppressive therapy with an undesirable safety profile, which includes accrued organ damage, infections and cancer. in 2018 across the 7MM despite being an off-label therapy for lupus.

Labelling 111

Labelling Immunization Immunity 111

Express Pharma

APRIL 24, 2023

Adults above 50 years of age and those suffering from chronic conditions such as diabetes, heart disease and kidney diseases are at an increased risk of developing shingles because of weakened immunity. The European Commission gave Shingrix approval for the prevention of shingles in adults 50 years of age or older in 2018.

Vaccines 97

Vaccines Immunization Immunity Diabetes 97

pharmaphorum

DECEMBER 22, 2021

CFI regulates the activity of the complement immune system which is over-activated in GA. The one-shot therapy aims to treat GA by delivering the gene for complement factor I (CFI) to the eye using an adeno-associated virus (AAV) vector. It has been fast-tracked by the FDA.

Immunization 105

Immunization Immunity 105

pharmaphorum

JANUARY 26, 2023

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. In 2018, England was the first country in Europe to provide access to a CAR-T cell therapy to treat these blood cancers, enabled via the Cancer Drugs Fund (CDF).

Chemotherapy 96

Chemotherapy Immunization Immunity Hospitals 96

Pharmaceutical Technology

JUNE 29, 2022

It merges a glycoprotein E antigen and an adjuvant system, AS01B, to induce a VZV-specific immune response that can aid in overcoming VZV immunity decline as people age. The Japanese MHLW granted initial approval for the vaccine in 2018 to prevent shingles in adults of the age 50 years and above.

Vaccines 64

Vaccines Immunity Immunization 64

pharmaphorum

JANUARY 19, 2023

The HD-MAP utilises an ultra-high-density array of projections – which are invisible to the naked human eye – applied to the skin to rapidly deliver a vaccine to immune cells immediately below the skin’s surface. In February 2022, the UK said it would pledge £160 million to CEPI to speed up vaccine development.

Vaccines 105

Vaccines Immunization Immunity 105

Pharma Mirror

FEBRUARY 11, 2021

In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). Samsung Biologics (KRX: 207940.KS) We are extremely glad to.

Immunity 52

Immunity Immunization Drug Development 52

pharmaphorum

JUNE 7, 2021

.” J&J paid Argenx a hefty $300 million upfront to secure rights to cusatuzumab (also known as JNJ-4550) in December 2018, and also made a $200 million equity investment in the Belgian company as part of a deal that had a total value of $1.6

Chemotherapy 64

Chemotherapy Immunization Immunity 64

pharmaphorum

JUNE 3, 2021

Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million. “Creating bispecific ISACs turbo-charged with potent immune stimulants is a novel concept that has tremendous potential for patients,” he added.

Immunity 52

Immunity Immunization 52

pharmaphorum

MARCH 31, 2021

FAP is found in particular on the “stroma” of a tumour, an ecosystem of connective tissue and various non-malignant cell types like blood and immune cells that is thought to be involved in the origin and spread of cancers. In 2018 it paid $2.1 billion.

Immunization 98

Immunization Immunity Hospitals 98

pharmaphorum

JANUARY 19, 2021

In 2018, Pfizer’s ALK and ROS1 inhibitor Xalkori (crizotinib) was cleared by NICE in England – via the Cancer Drugs Fund (CDF) – as well as in Scotland by the SMC as a first-line option for treating ROS1-positive advanced NSCLC in adults. NICE is due to deliver a verdict on this use for the drug in April.

Chemotherapy 98

Chemotherapy Immunization Immunity 98

Pharmaceutical Business Review

JANUARY 2, 2025

BRII-179 is designed to elicit strong B-cell and T-cell immunity by expressing Pre-S1, Pre-S2, and S HBV surface antigens. Brii Bio originally licensed BRII-179 from VBI Vaccines in December 2018 and has since expanded its exclusive license to global rights as of July 2023. This study is currently fully enrolled.

Vaccines 59

Vaccines Immunization Immunity 59

The Thyroid Pharmacist

JUNE 30, 2023

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

Compounding 98

Compounding Immunization Immunity Compounding Pharmacies 98

European Pharmaceutical Review

OCTOBER 19, 2023

The development of novel radiotherapeutics ushered in a new era in targeted treatment 1 for cancer, with two separate radiotherapeutic approvals in Europe and the US, in 2018 and 2022. Recent advancements for radiopharmaceuticals in oncology include a $1.4

Chemotherapy 105

Chemotherapy Compounding Immunization Immunity 105

Pharmaceutical Business Review

JULY 21, 2023

It is shown that by using a further adjuvant, two doses administered over 14 days demonstrate protective levels of immune response, and this can be particularly significant in response to a public health emergency involving anthrax. In 2019, the US government commenced procuring this product for national preparedness efforts.

Vaccines 52

Vaccines Immunity Immunization Packaging 52

pharmaphorum

SEPTEMBER 2, 2020

Vopratelimab is a monoclonal antibody that binds to and activates the Inducible T Cell CO-Stimulator (ICOS), a protein on the surface of certain T cells that is believed to stimulate an immune response against a patient’s cancer.

Immunization 71

Immunization Immunity 71

pharmaphorum

DECEMBER 21, 2020

The success of AbbVie’s Humira (adalimumab), which peaked at almost $20 billion in sales in 2018, demonstrates the potential of inflammatory diseases drugs to make mega-bucks. Principia also has a topical BTK inhibitor, PRN473, which is in phase 1 development for immune diseases that could benefit from local application to the skin.

Biosimilars 126

Biosimilars Chemotherapy Immunization Immunity 126

The Thyroid Pharmacist

DECEMBER 28, 2022

Vitamin D supports the immune system by enhancing the pathogen-fighting effects of white blood cells, which are important parts of immune defense. Supplementing with vitamin D can especially help to improve mood and cognitive function during the winter months, as well as improve immune function. I recommend doses of 1.5

Immunization 111

Immunization Immunity Clinical Pharmacology Doctor of Pharmacy 111

pharmaphorum

OCTOBER 19, 2022

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Nucleome’s co-founder and chief executive. . Dr Danuta Jeziorska. The post Nucleome raises £37.5m

Immunization 59

Immunization Immunity 59

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JANUARY 5, 2021

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint.

Chemotherapy 52

Chemotherapy Immunization Immunity Labelling 52

RX Note

JULY 5, 2025

Treatment directed at eradicating the inhibitor Immune tolerance induction (ITI) involves the regular infusion of factor VIII to induce antigen-specific tolerance. Although not commonly used in ITI protocols, immune modulation can improve tolerance success. Agents such as cyclophosphamide, intravenous immune globulin, rituximab.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Immunization Immunity Dosage 52

RX Note

JULY 5, 2025

Treatment directed at eradicating the inhibitor Immune tolerance induction (ITI) involves the regular infusion of factor VIII to induce antigen-specific tolerance. Although not commonly used in ITI protocols, immune modulation can improve tolerance success. Agents such as cyclophosphamide, intravenous immune globulin, rituximab.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Immunization Immunity Dosage 52

pharmaphorum

JANUARY 24, 2023

This includes treatments, such as immune checkpoint inhibitors , that are extraordinarily effective, but only work for certain patients. As such, the company signed a research agreement with GlaxoSmithKline in 2018, which saw the two companies use the genetic data gathered by 23andMe to discover novel, genetically validated drug targets.

Immunization 98

Immunization Immunity Drug Development 98

Pharmaceutical Technology

SEPTEMBER 14, 2022

Generation of an anti-tumour immune response can lead to complete and durable tumour regression across cancer types, with effector T cells being a critical component. Anti-CD25 monoclonal antibodies (mAbs) were developed as a means of targeting Tregs for antibody-dependent cellular cytotoxicity (ADCC), thereby eradicating this immune subset.

Immunity 52

Immunity Immunization 52

pharmaphorum

AUGUST 12, 2020

These tumour-associated macrophages (TAMs) have been enlisted by the tumour and suppress the local immune system and promote growth of cancer cells. Emactuzumab is a monoclonal antibody designed to target and deplete macrophages, a kind of white blood cell, in tumour tissue.

Immunization 52

Immunization Immunity 52

RX Note

MAY 1, 2025

Is the reaction due to an immune response to the drug (i.e. Drug allergy refers to adverse drug reactions due to hypersensitivity that mediates a specific immune response directed at the drug. NOTE: It is often difficult to distinguish between allergy and non-immune drug hypersensitivity reaction.

Adverse Reactions 52

Adverse Reactions Immunization Immunity Drug Development 52

pharmaphorum

JULY 1, 2025

billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio. billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio.

Diabetes 66

Diabetes Pharmaceutical Companies Pharmaceutical Companies Immunization 66

pharmaphorum

OCTOBER 19, 2022

Patients across the UK with chronic immune thrombocytopenia (ITP) now have another treatment option, after NICE backed use of Spanish drugmaker Grifols’ Tavlesse for adults with the rare blood disorder. It has also been made commercially available in France, Italy, Spain, Norway and the Czech Republic, as well as Turkey.

Immunization 52

Immunization Immunity Documentation 52